Metabolomic Analysis of Patients with Coronary Artery Disease and Acute Myocardial Infarction by Using Nuclear Magnetic Resonance Spectroscopy.

NMR spectroscopic metabolomic analysis identified distinct metabolic profiles distinguishing stable coronary artery disease from acute myocardial infarction.

• The study was a cross-sectional exploratory design comparing patients with stable CAD and AMI.
• The abstract reports 'significant variations in metabolite levels' between the two conditions.
• Metabolomics combined with pathway analysis was used to differentiate CAD from AMI.

Lactic acid emerged as a prominent marker in AMI patients, reflecting anaerobic glycolysis and acute ischemic stress.

• Lactic acid is described as 'a key metabolic product of anaerobic glycolysis'.
• The authors link high lactate levels to adverse outcomes.
• The abstract does not give specific concentrations or p-values.

Hypoxanthine was identified as another metabolite of interest in the study and is described as a key biomarker for myocardial ischemia.

• Hypoxanthine was found alongside lactic acid as a differentiating metabolite.
• The authors frame it as relevant to myocardial ischemia.

Metabolomics combined with pathway analysis highlighted metabolic dysregulation in CAD and AMI.

• Pathway analysis was used together with metabolite profiling to characterize the differences.
• The authors suggest the identified metabolites could serve as potential biomarkers for personalized prognostic and diagnostic strategies.

The authors state that larger studies are needed to validate the findings before clinical use.

• The study is described as exploratory and cross-sectional.
• The authors call for 'further large-scale studies' to validate the findings and incorporate them into clinical practice.